European journal of pharmacology
Cure8 research brief
Why This Matters
The study identifies thymoquinone as a compound that reduced inflammation and protected the intestinal barrier in a mouse colitis model, highlighting a possible new avenue for IBD drug discovery focused on the Notch pathway and barrier repair.
Who Should Pay Attention
Researchers, translational scientists, and clinicians interested in IBD mechanisms and preclinical drug discovery
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The paper reports that oral TQ given during 3% DSS-induced colitis in mice reduced disease activity scores, colonic tissue damage, and pro-inflammatory cytokines while increasing IL-10.
TQ also increased expression of tight-junction and mucin proteins (ZO-1, occludin, MUC2) and decreased markers of epithelial apoptosis (Bax, cleaved caspase-3) and increased Bcl-2. Parallel in vitro experiments in TNF-α–stimulated Caco-2 cells support inhibition of the Notch signalling pathway as a possible mechanism.
The study is preclinical: mice and cell models were used, not human patients. These results point to a potential therapeutic pathway (Notch inhibition and barrier protection) worth further research, but do not demonstrate safety or efficacy in people.
Keep In Mind
Findings come from DSS-induced colitis in mice and TNF-α–stimulated Caco-2 cells; these are common preclinical models but do not substitute for human clinical trials.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEuropean journal of pharmacology
AuthorsTong Sun, Qiang Tang, Linxia Xu +9 more
InstitutionDepartment of Gastroenterology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233000, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 15, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of Competing Interest All authors report no conflict of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Kaempferol in inflammatory bowel disease: regulating intestinal epithelial-fibroblast crosstalk
The study reports that kaempferol reduced inflammation, fibrosis, and barrier damage in mouse and cell models of colitis — mechanisms directly relevant to IBD progression and symptoms.
Celastrol ameliorates ulcerative colitis by inhibiting HSP90-mediated necroptosis of intestinal epithelial cells
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.
Glutaredoxin 1 facilitates colitis recovery by controlling glutathionylation and activity of STAT6 in M2 macrophages
The study proposes a new redox-regulatory pathway (Grx1–STAT6) that helps M2 macrophages drive tissue repair and colitis recovery in preclinical models, pointing to a possible new therapeutic target to promote...